The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Last month, the European Commission (EC) approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. 21 December 2023
Suzhou, China-based cancer company CStone Pharmaceuticals has inked a deal with French drugmaker Servier to sell certain rights to Tibsovo (ivosidenib). 21 December 2023
Lynparza (olaparib) has been recommended for use alongside abiraterone and prednisone or prednisolone for untreated hormone-relapsed metastatic prostate cancer in UK adults who cannot or will not have chemotherapy, regardless of biomarker status. 21 December 2023
Cambridge, USA-based mRNA cell engineering focused biotech Eterna Therapeutics has appointed Sanjeev Luther as president and chief executive and a member of the company's board of directors, effective January 1, 2024. 21 December 2023
French pharma major Sanofi today revealed it is discontinuing the global clinical development program of its antibody-drug conjugate (ADC) candidate tusamitamab ravtansine. 21 December 2023
Swedish drugmaker Calliditas Therapeutics has received full US Food and Drug Administration approval for Tarpeyo (budesonide), upgrading a previous nod under the Accelerated Approval scheme. 21 December 2023
For a second time, the US Food and Drug Administration has rejected a submission from Merck & Co for approval to market a chronic cough medication. 21 December 2023
India’s JB Chemicals & Pharmaceuticals saw its shares edge up 2% to 1,488.60 rupees, after it revealed it has acquired around 15 ophthalmology drugs from the Swiss pharma giant Novartis for rupees 964 crore or $116 million. 21 December 2023
Tonix Pharmaceuticals Holding Corp has announced highly statistically significant and clinically meaningful topline results in a second positive Phase III trial of TNX-102 SL for the management of fibromyalgia. 21 December 2023
The Indian pharmaceutical industry is firing on all cylinders, with exports showing a remarkable 8% increase year-to-date and a notable 29% surge in October alone, according to the chairman of Pharmexcil, the apex body for Indian pharma exports. 21 December 2023
Japanese drugmaker Shionogi has launched of siderophore cephalosporin antibiotic Fetroja (cefiderocol) intravenous infusion 1g vial in Japan. 21 December 2023
The US Food and Drug Administration (FDA) yesterday issued the final guidance Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization. 21 December 2023
Privately-held Swiss firm LimmaTech Biologics has announced a license agreement that grants the company exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02). 20 December 2023
As The World Health Organization (WHO) draws to a close COVAX, its pioneering global effort to distribute coronavirus vaccines, the agency said a new strain of the virus, JN.1, would be classed as a "variant of interest." 20 December 2023
UK pharma major GSK and China’s Hansoh Pharma have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor (TOPOi) payload. 20 December 2023
Shares of Dutch immunology specialist argenx slumped as much as 30% to 290.60 euros this morning, after it announced disappointing top-line results from the ADDRESS study 20 December 2023